Thomas R O'Brien1, Ruth M Pfeiffer2, Ashley Paquin3, Krystle A Lang Kuhs2, Sabrina Chen4, Herbert L Bonkovsky5, Brian R Edlin6, Charles D Howell7, Gregory D Kirk8, Mark H Kuniholm9, Timothy R Morgan10, Howard D Strickler9, David L Thomas8, Ludmila Prokunina-Olsson3. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. Electronic address: obrient@mail.nih.gov. 2. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. 3. Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. 4. Information Management Services, Calverton, MD, USA. 5. Department of Medicine and The Liver-Biliary-Pancreatic Center, Carolinas HealthCare System, Charlotte, NC, USA. 6. National Development and Research Institutes and Weill Cornell Medical College, New York, NY, USA. 7. Department of Medicine, Howard University College of Medicine, Washington, DC, USA. 8. Department of Epidemiology, The Johns Hopkins University, Baltimore, MD, USA. 9. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA. 10. VA Long Beach Healthcare System, Long Beach, CA, USA.
Abstract
BACKGROUND & AIMS: Genetic polymorphisms within the interferon lambda (IFN-λ) region are strongly associated with hepatitis C virus (HCV) clearance; the IFNL4-ΔG/TT (rs368234815) polymorphism, which controls the generation of IFN-λ4 protein, is more strongly associated with HCV clearance than rs12979860 (the 'IL28B variant'). An IFNL3 3' untranslated region polymorphism (rs4803217) has been proposed as a causal variant that may affect HCV clearance by altering IFNL3 mRNA stability. METHODS: We compared IFNL4-ΔG/TT and rs4803217 for association with response to pegylated-IFN-α/ribavirin in the VIRAHEP-C and HALT-C trials, and spontaneous HCV clearance in the ALIVE, UHS and WIHS studies. Genotyping was performed with TaqMan assays. We compared differences in mean reduction in HCV RNA levels by genotype and haplotype. For HCV clearance, we calculated p-values comparing c-statistics for IFNL4-ΔG/TT and rs4803217 genotypes by a bootstrap approach. RESULTS: Among European Americans, linkage disequilibrium between IFNL4-ΔG/TT and rs4803217 was strong (r(2)=0.89-0.99) and there were no significant differences between the variants. In African American (AA) individuals enrolled in VIRAHEP-C, HCV RNA at treatment day 28 was more strongly associated with IFNL4-ΔG/TT than rs4803217 (p=0.003); the IFNL4-ΔG:rs4803217-G haplotype, which includes the putatively favorable IFNL3 allele, was actually associated with the poorest day 28 response (p=0.03, comparison to IFNL4-ΔG:rs4803217-T haplotype). Among AA participants, associations were stronger for IFNL4-ΔG/TT than rs4803217 for undetectable HCV RNA at week 24 in Virahep-C (p=0.03) and week 20 in HALT-C (p=0.03), as well as for spontaneous HCV clearance (p=0.048). CONCLUSION: IFNL4-ΔG/TT is the primary IFN-λ region polymorphism for impaired HCV clearance. Published by Elsevier B.V.
BACKGROUND & AIMS: Genetic polymorphisms within the interferon lambda (IFN-λ) region are strongly associated with hepatitis C virus (HCV) clearance; the IFNL4-ΔG/TT (rs368234815) polymorphism, which controls the generation of IFN-λ4 protein, is more strongly associated with HCV clearance than rs12979860 (the 'IL28B variant'). An IFNL3 3' untranslated region polymorphism (rs4803217) has been proposed as a causal variant that may affect HCV clearance by altering IFNL3 mRNA stability. METHODS: We compared IFNL4-ΔG/TT and rs4803217 for association with response to pegylated-IFN-α/ribavirin in the VIRAHEP-C and HALT-C trials, and spontaneous HCV clearance in the ALIVE, UHS and WIHS studies. Genotyping was performed with TaqMan assays. We compared differences in mean reduction in HCV RNA levels by genotype and haplotype. For HCV clearance, we calculated p-values comparing c-statistics for IFNL4-ΔG/TT and rs4803217 genotypes by a bootstrap approach. RESULTS: Among European Americans, linkage disequilibrium between IFNL4-ΔG/TT and rs4803217 was strong (r(2)=0.89-0.99) and there were no significant differences between the variants. In African American (AA) individuals enrolled in VIRAHEP-C, HCV RNA at treatment day 28 was more strongly associated with IFNL4-ΔG/TT than rs4803217 (p=0.003); the IFNL4-ΔG:rs4803217-G haplotype, which includes the putatively favorable IFNL3 allele, was actually associated with the poorest day 28 response (p=0.03, comparison to IFNL4-ΔG:rs4803217-T haplotype). Among AA participants, associations were stronger for IFNL4-ΔG/TT than rs4803217 for undetectable HCV RNA at week 24 in Virahep-C (p=0.03) and week 20 in HALT-C (p=0.03), as well as for spontaneous HCV clearance (p=0.048). CONCLUSION:IFNL4-ΔG/TT is the primary IFN-λ region polymorphism for impaired HCV clearance. Published by Elsevier B.V.
Authors: Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher Journal: Nat Immunol Date: 2002-12-02 Impact factor: 25.606
Authors: Melanie C Bacon; Viktor von Wyl; Christine Alden; Gerald Sharp; Esther Robison; Nancy Hessol; Stephen Gange; Yvonne Barranday; Susan Holman; Kathleen Weber; Mary A Young Journal: Clin Diagn Lab Immunol Date: 2005-09
Authors: Sergei V Kotenko; Grant Gallagher; Vitaliy V Baurin; Anita Lewis-Antes; Meiling Shen; Nital K Shah; Jerome A Langer; Faruk Sheikh; Harold Dickensheets; Raymond P Donnelly Journal: Nat Immunol Date: 2002-12-16 Impact factor: 25.606
Authors: Hari S Conjeevaram; Michael W Fried; Lennox J Jeffers; Norah A Terrault; Thelma E Wiley-Lucas; Nezam Afdhal; Robert S Brown; Steven H Belle; Jay H Hoofnagle; David E Kleiner; Charles D Howell Journal: Gastroenterology Date: 2006-08 Impact factor: 22.682
Authors: Adrian M Di Bisceglie; Mitchell L Shiffman; Gregory T Everson; Karen L Lindsay; James E Everhart; Elizabeth C Wright; William M Lee; Anna S Lok; Herbert L Bonkovsky; Timothy R Morgan; Marc G Ghany; Chihiro Morishima; Kristin K Snow; Jules L Dienstag Journal: N Engl J Med Date: 2008-12-04 Impact factor: 91.245
Authors: William M Lee; Jules L Dienstag; Karen L Lindsay; Anna S Lok; Herbert L Bonkovsky; Mitchell L Shiffman; Gregory T Everson; Adrian M Di Bisceglie; Timothy R Morgan; Marc G Ghany; Chihiro Morishima; Elizabeth C Wright; James E Everhart Journal: Control Clin Trials Date: 2004-10
Authors: Fan-Chen Tseng; Thomas R O'Brien; Mingdong Zhang; Alex H Kral; Betty A Ortiz-Conde; Jennifer Lorvick; Michael P Busch; Brian R Edlin Journal: Hepatology Date: 2007-09 Impact factor: 17.425
Authors: Thomas R O'Brien; Howard A Young; Raymond P Donnelly; Ludmila Prokunina-Olsson Journal: J Interferon Cytokine Res Date: 2019-04-17 Impact factor: 2.607
Authors: Jonathan R Honegger; Dana Tedesco; Jennifer A Kohout; Mona R Prasad; Aryn A Price; Tera Lindquist; Samantha Ohmer; Melissa Moore-Clingenpeel; Arash Grakoui; Christopher M Walker Journal: Proc Natl Acad Sci U S A Date: 2016-09-06 Impact factor: 11.205
Authors: Aryn A Price; Dana Tedesco; Mona R Prasad; Kimberly A Workowski; Christopher M Walker; Mehul S Suthar; Jonathan R Honegger; Arash Grakoui Journal: Proc Natl Acad Sci U S A Date: 2016-09-06 Impact factor: 11.205
Authors: Hawwa Alao; Maggie Cam; Chithra Keembiyehetty; Fang Zhang; Elisavet Serti; Daniel Suarez; Heiyoung Park; Nicolaas H Fourie; Elizabeth C Wright; Wendy A Henderson; Qisheng Li; T Jake Liang; Barbara Rehermann; Marc G Ghany Journal: Hepatology Date: 2018-07-16 Impact factor: 17.425
Authors: Adam D Kenney; James A Dowdle; Leonia Bozzacco; Temet M McMichael; Corine St Gelais; Amanda R Panfil; Yan Sun; Larry S Schlesinger; Matthew Z Anderson; Patrick L Green; Carolina B López; Brad R Rosenberg; Li Wu; Jacob S Yount Journal: Annu Rev Genet Date: 2017-08-30 Impact factor: 16.830
Authors: Mohammed Eslam; Duncan McLeod; Kebitsaone Simon Kelaeng; Alessandra Mangia; Thomas Berg; Khaled Thabet; William L Irving; Gregory J Dore; David Sheridan; Henning Grønbæk; Maria Lorena Abate; Rune Hartmann; Elisabetta Bugianesi; Ulrich Spengler; Angela Rojas; David R Booth; Martin Weltman; Lindsay Mollison; Wendy Cheng; Stephen Riordan; Hema Mahajan; Janett Fischer; Jacob Nattermann; Mark W Douglas; Christopher Liddle; Elizabeth Powell; Manuel Romero-Gomez; Jacob George Journal: Nat Genet Date: 2017-04-10 Impact factor: 38.330
Authors: Eric G Meissner; Dongjun Chung; Betty Tsao; David W Haas; Netanya S Utay Journal: AIDS Res Hum Retroviruses Date: 2020-11-11 Impact factor: 1.723